Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Interference01:23

RNA Interference

26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

800
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
800

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TopBP1 biomolecular condensates as a new therapeutic target in advanced-stage colorectal cancer.

eLife·2025
Same author

[Nobel Prize in physiology or medicine 2024: Victor Ambros and Gary Ruvkun - The discovery of microRNAs, revealing a New World in genetics].

Medecine sciences : M/S·2025
Same author

HIV-1 assembly - when virology meets biophysics.

Journal of cell science·2024
Same author

A new perspective on microRNA-guided gene regulation specificity, and its potential generalization to transcription factors and RNA-binding proteins.

Nucleic acids research·2024
Same author

The multifunction <i>Coxiella</i> effector Vice stimulates macropinocytosis and interferes with the ESCRT machinery.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same author

Looking for a needle in a haystack: de novo phenotypic target identification reveals Hippo pathway-mediated miR-202 regulation of egg production.

Nucleic acids research·2023

Related Experiment Video

Updated: Jul 28, 2025

MISSION esiRNA for RNAi Screening in Mammalian Cells
15:31

MISSION esiRNA for RNAi Screening in Mammalian Cells

Published on: May 12, 2010

16.4K

Biochemistry-informed design selects potent siRNAs against SARS-CoV-2.

Élisabeth Houbron1, Sophie Mockly1,2, Sophia Rafasse3

  • 1Institut de Génétique Humaine, UMR 9002 CNRS and University of Montpellier, Montpellier, France.

RNA Biology
|June 5, 2023
PubMed
Summary

Novel RNA interference (RNAi) therapeutics offer a new strategy against SARS-CoV-2. This approach uses advanced computational tools to design small interfering RNAs (siRNAs) for effective gene silencing and broad viral coverage.

Keywords:
RNA accessibilityRNAiSARS-CoV-2siRNAsiRNA design

More Related Videos

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
12:23

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

1.7K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K

Related Experiment Videos

Last Updated: Jul 28, 2025

MISSION esiRNA for RNAi Screening in Mammalian Cells
15:31

MISSION esiRNA for RNAi Screening in Mammalian Cells

Published on: May 12, 2010

16.4K
In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses
12:23

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

1.7K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.1K

Area of Science:

  • Molecular Biology
  • Virology
  • Bioinformatics

Background:

  • RNA interference (RNAi) is a powerful gene silencing technique widely used in research.
  • Clinical applications of RNAi are emerging, with several small interfering RNAs (siRNAs) approved for human diseases.
  • The COVID-19 pandemic highlights the need for adaptable antiviral therapies.

Purpose of the Study:

  • To develop novel siRNA therapeutics against SARS-CoV-2 using an advanced computational design approach.
  • To assess the antiviral activity and variant coverage of designed siRNAs.
  • To establish RNAi as a versatile antiviral therapeutic strategy.

Main Methods:

  • Utilized an updated mechanistic description of RNAi to design siRNAs computationally.
  • Incorporated strategies to allow beneficial mismatches and optimize siRNA duplex asymmetry.
  • Proposed 8 siRNAs targeting SARS-CoV-2 and assessed their efficacy ex vivo.

Main Results:

  • Ex vivo assessment confirmed high antiviral activity for 6 out of 8 designed siRNAs.
  • Achieved excellent variant coverage, with combinations of 3 siRNAs recognizing all sequenced variants (as of September 2022).
  • The computational approach is generalizable to other viruses with available genome databases.

Conclusions:

  • The developed siRNA design pipeline shows promise for creating effective SARS-CoV-2 treatments.
  • RNAi represents a versatile and efficient antiviral therapeutic strategy, adaptable to new variants and viruses.
  • Improvements in siRNA delivery will further enhance the clinical potential of this approach.